{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:28:07Z","timestamp":1790962087502,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004400","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000}}],"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Preclinical animal studies have suggested that myeloid cell\u2013synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing whether patients with atrial fibrillation taking direct factor Xa inhibitors have lower risk of cancer and cancer-related mortality than patients taking the direct thrombin inhibitor dabigatran.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>This nationwide population-based cohort study in Denmark included adult patients with atrial fibrillation and without a history of cancer, who started taking a factor Xa inhibitor or dabigatran between 2011 and 2015. Data on medical history, outcomes, and drug use were acquired through Danish healthcare registries. The primary outcome was any cancer. Secondary outcomes were cancer-related mortality and all-cause mortality. Outcome events were assessed during 5 years of follow-up in an intention-to-treat analysis. The propensity score-based inverse probability of treatment weighting was used to compute cumulative incidence and subdistribution hazard ratios (SHRs) and corresponding 95% confidence intervals (CIs), with death as a competing event. Propensity scores were estimated using logistic regression and including in the model sex, age group at index date, comorbidities, and use of comedications. A total of 11,742 patients with atrial fibrillation starting a factor Xa inhibitor and 11,970 patients starting dabigatran were included. Mean age was 75.2 years (standard deviation [SD] 11.2) in the factor Xa cohort and 71.7 years (SD 11.1) in the dabigatran cohort. On the basis of the propensity score-weighted models, after 5 years of follow-up, no substantial difference in the cumulative incidence of cancer was observed between the factor Xa inhibitor (2,157\/23,711; 9.11%, 95% CI [8.61%,9.63%]) and dabigatran (2,294\/23,715; 9.68%, 95% CI [9.14%,10.25%]) groups (SHR 0.94, 95% CI [0.89,1.00], <jats:italic>P<\/jats:italic> value 0.0357). We observed no difference in cancer-related mortality (factor Xa inhibitors cohort 1,028\/23,711; 4.33%, 95% CI [4.02%,4.68%]. Dabigatran cohort 1,001\/23,715; 4.22%, 95% CI [3.83%,4.66%]; SHR 1.03, 95% CI [0.94,1.12]), but all-cause mortality was higher in the factor Xa inhibitor cohort (factor Xa inhibitors cohort 7,416\/23,711; 31.31%, 95% CI [30.37%,32.29%]. Dabigatran cohort 6,531\/23,715; 27.56%, 95% CI [26.69%,28.45%]; HR 1.17, 95% CI [1.13,1.21]). The main limitations of the study were the possibility of residual confounding and the short follow-up period.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this population based cohort study, factor Xa inhibitor use was not associated with an overall lower incidence of cancer or cancer-related mortality when compared to dabigatran. We did observe an increase in all-cause mortality in the factor Xa inhibitor cohort.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004400","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T17:37:44Z","timestamp":1719855464000},"page":"e1004400","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-5402","authenticated-orcid":true,"given":"Floris","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-2212","authenticated-orcid":true,"given":"Erzs\u00e9bet","family":"Horv\u00e1th-Puh\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-2303","authenticated-orcid":true,"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-6346","authenticated-orcid":true,"given":"Nick","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-7040","authenticated-orcid":true,"given":"Henrik T.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"pmed.1004400.ref001","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis.","volume":"45","author":"AMR Rondon","year":"2019","journal-title":"Semin Thromb Hemost."},{"key":"pmed.1004400.ref002","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2006.10.002","article-title":"Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype","volume":"10","author":"ML Nierodzik","year":"2006","journal-title":"Cancer Cell"},{"key":"pmed.1004400.ref003","first-page":"2997","article-title":"Tissue factor\/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism","volume":"63","author":"TA Hembrough","year":"2003","journal-title":"Cancer Res"},{"key":"pmed.1004400.ref004","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2007-07-101048","article-title":"Inhibition of tissue factor signaling suppresses tumor growth","volume":"111","author":"HH Versteeg","year":"2008","journal-title":"Blood"},{"key":"pmed.1004400.ref005","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0049-3848(10)70010-4","article-title":"Tissue factor in cancer progression and angiogenesis","volume":"125","author":"W Ruf","year":"2010","journal-title":"Thromb Res"},{"key":"pmed.1004400.ref006","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","article-title":"Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis","volume":"105","author":"JL Yu","year":"2005","journal-title":"Blood"},{"key":"pmed.1004400.ref007","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","article-title":"Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival.","volume":"27","author":"NM Kuderer","year":"2009","journal-title":"J Clin Oncol"},{"key":"pmed.1004400.ref008","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy.","volume":"23","author":"CPW Klerk","year":"2005","journal-title":"J Clin Oncol."},{"key":"pmed.1004400.ref009","doi-asserted-by":"crossref","first-page":"1801220","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"G Meyer","year":"2018","journal-title":"Eur Respir J"},{"key":"pmed.1004400.ref010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.","volume":"34","author":"F Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"key":"pmed.1004400.ref011","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jso.20728","article-title":"Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.","volume":"95","author":"F Icli","year":"2007","journal-title":"J Surg Oncol"},{"key":"pmed.1004400.ref012","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"D Sanford","year":"2014","journal-title":"J Thromb Haemost"},{"key":"pmed.1004400.ref013","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell\u2013synthesized coagulation factor X dampens antitumor immunity.","volume":"4","author":"C Graf","year":"2019","journal-title":"Sci Immunol"},{"key":"pmed.1004400.ref014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/CLEP.S179083","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records.","volume":"11","author":"M Schmidt","year":"2019","journal-title":"Clin Epidemiol."},{"key":"pmed.1004400.ref015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National patient registry: A review of content, data quality, and research potential.","volume":"7","author":"M Schmidt","year":"2015","journal-title":"Clin Epidemiol."},{"key":"pmed.1004400.ref016","first-page":"798","article-title":"Data resource profile: The Danish national prescription registry.","volume":"46","author":"A Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"pmed.1004400.ref017","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish Cancer Registry.","volume":"39","author":"ML Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"key":"pmed.1004400.ref018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish Register of Causes of Death.","volume":"39","author":"K. Helweg-Larsen","year":"2011","journal-title":"Scand J Public Health."},{"key":"pmed.1004400.ref019","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"M Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"pmed.1004400.ref020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/14017431.2012.673728","article-title":"Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry","volume":"46","author":"TA Rix","year":"2012","journal-title":"Scand Cardiovasc J"},{"key":"pmed.1004400.ref021","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation","volume":"33","author":"AJ Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"pmed.1004400.ref022","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"pmed.1004400.ref023","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"pmed.1004400.ref024","article-title":"World Cancer Research Fund. Diet, nutrition, physical activity and cancer: a global perspective.","year":"2018","journal-title":"Continuous Update Project Expert. Report"},{"key":"pmed.1004400.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(97)00648-X","article-title":"Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996.","volume":"17","author":"P Boyle","year":"1997","journal-title":"Lung Cancer"},{"key":"pmed.1004400.ref026","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(06)70577-0","article-title":"Alcohol and cancer","volume":"7","author":"P Boffetta","year":"2006","journal-title":"Lancet Oncol"},{"key":"pmed.1004400.ref027","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1093\/eurheartj\/ehz964","article-title":"Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation","volume":"43","author":"PV Rasmussen","year":"2022","journal-title":"Eur Heart J"},{"key":"pmed.1004400.ref028","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/0284186X.2021.2024879","article-title":"Drop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020.","volume":"61","author":"CW Skovlund","year":"2022","journal-title":"Acta Oncol (Madr)."},{"key":"pmed.1004400.ref029","article-title":"The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.","volume":"13","author":"SK Kim","year":"2022","journal-title":"Front Pharmacol"},{"key":"pmed.1004400.ref030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016836","article-title":"New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation.","volume":"9","author":"S Raposeiras Roub\u00edn","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"pmed.1004400.ref031","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"P Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"pmed.1004400.ref032","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/bcp.14071","article-title":"Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008\u20132015): A cross-national drug utilization study.","volume":"85","author":"L Ib\u00e1\u00f1ez","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"pmed.1004400.ref033","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.","volume":"176","author":"DJ Graham","year":"2016","journal-title":"JAMA Intern Med."},{"key":"pmed.1004400.ref034","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"pmed.1004400.ref035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s41999-021-00537-w","article-title":"Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines.","volume":"13","author":"MC Polidori","year":"2021","journal-title":"Eur Geriatr Med"},{"key":"pmed.1004400.ref036","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation","volume":"175","author":"WCY Lau","year":"2022","journal-title":"Ann Intern Med"},{"key":"pmed.1004400.ref037","first-page":"12","article-title":"Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2","author":"A Metelli","year":"2020","journal-title":"Sci Transl Med"},{"key":"pmed.1004400.ref038","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/epirev\/mxq021","article-title":"Measuring Mortality Reductions in Cancer Screening Trials.","volume":"33","author":"JA Hanley","year":"2011","journal-title":"Epidemiol Rev"},{"key":"pmed.1004400.ref039","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0040-1714213","article-title":"The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation","volume":"120","author":"D Abrahami","year":"2020","journal-title":"Thromb Haemost"},{"key":"pmed.1004400.ref040","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1002\/cam4.4241","article-title":"Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban","volume":"10","author":"Y Lin","year":"2021","journal-title":"Cancer Med"},{"key":"pmed.1004400.ref041","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004400","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T17:46:04Z","timestamp":1721151964000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004400"}},"subtitle":[],"editor":[{"given":"Aadel A.","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004400","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004400","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}